Sosei Heptares’ Partner, Pfizer, Progresses Its GLP-1 Receptor Agonist PF-06954522 into a Phase 1 Trial

Written by Customer Service on November 5, 2023. Posted in Public Companies.

PF-06954522 was introduced into Pfizer’s Internal Medicine focused clinical pipeline as part of its Q3 2023 results presentation Tokyo, Japan and Cambridge, UK, 06 November 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) has been notified by Pfizer that it has entered a new oral small molecule GLP-1 receptor agonist into a Phase 1 clinical trial. PF-06954522 was discovered by Pfizer scientists during a multi-target research collaboration in which Pfizer had access to Sosei Heptares’ proprietary StaR® (stabilized receptor) technology. Pfizer recently detailed the entry of PF-06954522 into its Internal Medicine focused clinical pipeline as part of its Q3 2023 results on 31 October 2023. Dr. Matt Barnes, President of Heptares Therapeutics and Head of UK R&D, commented: “We are delighted to see the progression...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioNTech SE – BNTX

Written by Customer Service on November 5, 2023. Posted in Earnings Releases And Operating Results.

NEW YORK, Nov. 05, 2023 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether BioNTech and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On October 16, 2023, BioNTech issued a press release regarding Pfizer Inc. (“Pfizer”), a collaboration partner of BioNTech, “announc[ing] a non-cash charge for inventory write-offs and other charges related to COMIRNATY of $0.9 billion. The Company has been informed by Pfizer that the majority of the write-offs relate to raw materials, mainly...

Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg Barzolvolimab

Written by Customer Service on November 5, 2023. Posted in Public Companies.

– Response observed as early as week 1 and durable for up to 16 weeks –– Data support important role for mast cells in the pathogenesis of PN and potentially other chronic itch indications –– Phase 2 PN study to initiate in early 2024 –– Conference call to be held on Monday, November 6th at 8:00 am ET to discuss study results – HAMPTON, N.J., Nov. 05, 2023 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data from the Company’s Phase 1b study of barzolvolimab in prurigo nodularis (PN). Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for the function and survival of the mast cell. Mast cells are believed to play an important...

Tenaris to Commence a USD 300 million First Tranche of its USD 1.2 Billion Share Buyback Program

Written by Customer Service on November 5, 2023. Posted in Public Companies.

LUXEMBOURG, Nov. 05, 2023 (GLOBE NEWSWIRE) — Tenaris S.A. (NYSE and Mexico: TS and EXM Italy: TEN) (“Tenaris”) announced today that pursuant to its Share Buyback Program (the “Program”) announced on November 1, 2023, covering up to $1.2 billion to be executed in the open market with the intent to cancel the ordinary shares acquired through the Program, Tenaris has entered into a non-discretionary buyback agreement with a primary financial institution (the “Bank”). The Bank will make its trading decisions concerning the timing of the purchases of Tenaris’s ordinary shares independently of and uninfluenced by Tenaris and will act in compliance with applicable rules and regulations, including the Market Abuse Regulation 596/2014 and the Commission Delegated Regulation (EU) 2016/1052 (the “Regulations”). Under the buyback agreement,...

MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis

Written by Customer Service on November 5, 2023. Posted in Public Companies.

MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis First placebo-controlled randomized trial in active psoriatic arthritis (PsA) using a Nanobody® to report positive topline results in support of potential best-in-class profile Primary endpoint ACR50 met with up to 47% (p

M	T	W	T	F	S	S
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30

Day: November 5, 2023